ALTRUBIO
AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. AltruBio International in Delaware with principal office in SFO Bay Area California is a biopharmaceutical company integrated globally and virtually to develop targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. With its R&D foundation in Taipei Taiwan since June 2000, AbGenomics has been focusing on the discover... y and development of novel therapeutics for unmet medical needs. Their R&D scientists built an efficient discovery platform to identify and validate novel antibody therapeutics. Currently, AbGenomics has several potential therapeutic antibodies targeting autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, and other solid tumors in various development stages.
ALTRUBIO
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2000-06-01
Address:
Los Altos, California, United States
Country:
United States
Website Url:
http://www.altrubio.com
Total Employee:
11+
Status:
Active
Contact:
(650) 988-9912
Email Addresses:
[email protected]
Total Funding:
102.61 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arvinas
Arvinas focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, and autoimmune.
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
CAM Capital
CAM Capital investment in Series A - AltruBio
aMoon Fund
aMoon Fund investment in Series A - AltruBio
BVF Partners
BVF Partners investment in Series A - AltruBio
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-13 | AltruBio snags a CMO after pivot from oncology to immunology |
| 2021-08-09 | AltruBio Strengthens Management Team With Appointment of Jeroen Grasman as Chief Financial Officer |
Official Site Inspections
http://www.altrubio.com Semrush global rank: 1.78 M Semrush visits lastest month: 13.03 K
Unable to get host informations!!!
More informations about "AltruBio" on Search Engine
AltruBio
AltruBio fulfills unmet medical needs by creating antibody-targeted therapy. Science, passion and a global vision make it possible. Learn more about how we are improving patients’ lives.See details»
AltruBio - Crunchbase Company Profile & Funding
Company Type For Profit. Contact Email [email protected]. Phone Number (650) 988-9912. AltruBio is focused on developing targeted antibody therapeutics for the …See details»
New name, new board, new focus: AltruBio relaunches with …
By Annalee Armstrong Apr 15, 2021 8:00am. AltruBio would like to reintroduce itself. After shifting from oncology to immunology, swapping out the board and completing a name …See details»
AltruBio Inc. | LinkedIn
About us. AltruBio is developing first-in-class immune-modulators targeting diseases of #immunology and #inflammation. Its world-class global team brings a breadth of …See details»
AltruBio Announces FDA Clearance of IND Application for
SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel …See details»
AltruBio Raises $63 Million Series A Round To Continue Its …
Apr 15, 2021 AltruBio is a privately held biotechnology company headquartered in the San Francisco Bay Area that is focused on developing novel therapeutics for the …See details»
AltruBio Announces Completion of Enrollment in Phase 1 Clinical …
SAN FRANCISCO, May 12, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel …See details»
AltruBio Announces FDA Clearance of IND Application for ALTB …
SAN FRANCISCO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel …See details»
AltruBio Announces Enrollment of First Patient in Phase 2
SAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel …See details»
AltruBio Corporate Mission - YouTube
Mar 23, 2023 AltruBio is developing first-in-class immune-modulators targeting diseases of immunology and inflammation. Its world-class global team brings a breadth of ex...See details»
AltruBio Announces Positive Topline Data from Phase 1 Trial of …
SAN FRANCISCO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel …See details»
AltruBio, Inc. - BIO International Convention | BIO
Jun 5, 2023 Schedule & Agenda. AltruBio, Inc. 5:00 PM - 5:15 PM (EDT), Monday, June 5, 2023 ・ Session Room 104C. AltruBio is a privately held, clinical stage …See details»
AltruBio - Funding, Financials, Valuation & Investors - Crunchbase
AltruBio has raised a total of. $102.6M. in funding over 4 rounds. Their latest funding was raised on Apr 15, 2021 from a Series A round. AltruBio is funded by 3 investors. CAM …See details»
AltruBio - Crunchbase
AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune related inflammatory diseases. ... Products. Resources. Pricing. …See details»
AltruBio to Participate in Upcoming May 2024 Medical Conferences
SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel …See details»
AltruBio | CipherBio
AltruBio is a privately held biotechnology company headquartered in the San Francisco Bay Area that is focused on developing novel antibody therapeutics for the treatment of …See details»
AltruBio to Present New Phase 1b Data Evaluating Neihulizumab …
SAN FRANCISCO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel …See details»
Leiolizumab - AltruBio - AdisInsight - Springer
Dec 11, 2023 Most Recent Events. 07 Dec 2023 AltruBio initiates enrolment in a phase IIa trial for Ulcerative colitis. 13 Nov 2023 Phase-II clinical trials in Ulcerative colitis …See details»
AltruBio Announces Enrollment of First Patient in Phase 2 Clinical ...
SAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel …See details»